SLS begins Phase 2 AML trial with first patient enrolled

SLS begins Phase 2 AML trial with first patient enrolled

Rojgar4u Team March 12, 2026

5

SLS begins Phase 2 AML trial with first patient enrolled

SELLAS Life Sciences Group Inc. enrolled the first patient in a Phase 2 trial of SLS009, a selective CDK9 inhibitor for acute myeloid leukaemia (AML). The study will enroll about 80 patients across two high-priority groups to test the drugs effectiveness in frontline treatment, potentially supporting future registrational development.

Sponsored Advertisement

Did you find this helpful?

Your support helps us create more free content.

Comment

Share & Earn 0

WhatsApp Facebook Telegram X LinkedIn

Discussion (0)

Please Login to comment.

No comments yet. Be the first!

More Recent News

06 Apr Why do we always see the same side of the Moon?

06 Apr IN PICS - Iranian embassies around the world mock Trump and US with memes

06 Apr US-Israel attack leading science university in Iran

06 Apr Why did humanity take 50 years to return to the Moon?